Head and neck squamous cell carcinoma
Therapeutic area
Oncology
Rare disease
Yes
- Definition
- A squamous cell carcinoma that arises from any of the following anatomic sites: lip and oral cavity, nasal cavity, paranasal sinuses, pharynx, larynx, and salivary glands.
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Head and neck squamous cell carcinoma
- Therapeutic area
- Oncology
- head and neck squamous cell carcinoma
- HNSCC
- SCCHN
- craniocervical region squamous cell carcinoma
- head and neck squamous cell carcinoma
- squamous cell carcinoma of head and neck
- squamous cell carcinoma of the head and neck
- squamous cell carcinoma, head and neck, somatic
- carcinoma of the head and neck
- squamous cell carcinoma, head and neck
- All therapeutic areas
- Oncology
- Severity
- Severe
- MONDO ID
- MONDO:0010150
- Parent condition
- MONDO:0002038
Related records
Broader conditions (14)
- Cancer
- Cancer or benign tumor
- Carcinoma
- Disease
- Disease by etiologic mechanism
- Epithelial neoplasm
- Head and neck cancer
- Head and neck carcinoma
- Head and neck neoplasm
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
- Squamous cell carcinoma
- Squamous cell neoplasm
Narrower conditions (38)
- Conjunctival squamous cell carcinoma
- Cornea squamous cell carcinoma
- Ethmoid sinus squamous cell carcinoma
- External ear squamous cell carcinoma
- Frontal sinus squamous cell carcinoma
- Glottis squamous cell carcinoma
- Glottis verrucous carcinoma
- Hypopharynx squamous cell carcinoma
- Lacrimal gland squamous cell carcinoma
- Laryngeal squamous cell carcinoma
- Larynx verrucous carcinoma
- Lip and oral cavity squamous cell carcinoma
- Maxillary sinus squamous cell carcinoma
- Middle ear squamous cell carcinoma
- Nasal cavity and paranasal sinus squamous cell carcinoma
- Nasal cavity squamous cell carcinoma
- Nasopharyngeal squamous cell carcinoma
- Non-keratinizing sinonasal squamous cell carcinoma
- Oral cavity squamous cell carcinoma
- Oropharynx squamous cell carcinoma
Trials (1,973)
- "Ultra-High Frequency intraOral UltraSonography of the TONgue" (HOUSTON)
- (89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma
- [18F]-AraG PET Imaging in LA HNSCC
- [68Ga]Ga-FAPI-46 in Staging of Head and Neck Carcinomas
- 0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck
- 10-year Retrospective Study of Oral and Maxillofacial Squamous Cell Carcinoma
- 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
- 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- 18F-FDG PET/CT Versus 18F-FDG PET/MRI in Detecting Locoregional Recurrence 3 Months After CRT in Head and Neck SCC
- 2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma
- 2B or Not 2B? Shoulder Function After Level 2B Neck Dissection: A Randomized Controlled Study
- 3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized Trial
- 3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx
- 3D Specimen Maps for RT Planning
- 4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC
- 5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC
- 5-Fluorouracil Response and Optimization STudy (The FROST Trial)
- 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
- 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
- 89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC
Approved drugs (9)
- Cemiplimab
- Cetuximab
- Cosibelimab
- Docetaxel anhydrous
- Hydroxyurea
- Nivolumab
- Pembrolizumab
- Retifanlimab
- Temoporfin
Drugs in development (190)
- Abemaciclib Phase 2
- Acalabrutinib Phase 2
- Adakitug Phase 2
- Adavosertib Phase 1
- Adebrelimab Phase 2
- Afatinib Phase 3
- Albumin human Phase 2
- Aldesleukin Phase 1
- Alisertib Phase 1
- Alpelisib Phase 2
- AMG-319 Phase 2
- Amivantamab Phase 1
- Astuprotimut-R Phase 1
- Atezolizumab Phase 3
- Avelumab Phase 3
- Axitinib Phase 2
- Azacitidine Phase 1
- Becotatug vedotin Phase 3
- Benmelstobart Phase 3
- Bevacizumab Phase 2